Form 4: Amphastar CFO Peters Reports RSU Tax Withholding

Amphastar Pharmaceuticals' CFO, William J. Peters, reported the disposition of 1,744 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• William J. Peters, CFO, EVP & Treasurer, and Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported a transaction on March 4, 2026.
• 1,744 shares of common stock were disposed of at a price of $19.96 per share.
• This disposition was to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Peters beneficially owns 123,786 shares of common stock.
• The reported beneficial ownership includes 545 shares acquired on May 31, 2025, through the Issuer's 2014 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine administrative transaction related to executive compensation rather than a strategic move or a reflection of company performance.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive.

Negatives

• No direct negatives for the company; the disposition is a routine tax withholding.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as tax-related dispositions following RSU vesting, are common across the pharmaceutical industry and generally do not signal a change in company fundamentals or executive confidence.

Comparison to Industry Standards

• Routine tax-related dispositions of shares upon RSU vesting are standard practice for executive compensation across publicly traded companies, including peers in the pharmaceutical sector like Pfizer or Johnson & Johnson, where executives often sell a portion of vested equity to cover tax obligations. This transaction aligns with typical compensation plan structures.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Transaction, William J. Peters, CFO, Restricted Stock Units, RSU, Tax Withholding, Stock Ownership